CD8A and Epstein-Barr virus infection: However, virus-dependent CD8+ T cell activation and expansion was likely curbed by FK506 treatment in vivo and/or the associated loss of CD4+ T cell help, even though high overall rates of activation and expansion were achieved during EBV infection.